WINNIPEG – TheNewswire - August 1, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced the recent appointment of Mr. Thomas Wellner as the new Chairman of the Board subsequent to his election as a director at the Annual and Special Meeting of the Shareholders (“ASM”) on June 25, 2025. Mr. Wellner was selected by the board to stand for election and was appointed as board chairman based on his outstanding leadership experience in biotechnology and pharmaceutical companies, in-depth governance experience, and extensive global business network.

 “I am honoured to be joining Cytophage’s Board of Directors and grateful for the opportunity to serve as Board Chair at such a pivotal stage of the Company’s product advancements,” said Mr. Wellner. “I am excited to work alongside my fellow board members and to leverage my experience to help Cytophage progress with making their cutting-edge phage technology a mainstream commercial solution for global animal and human health challenges.”

Tom Wellner is a highly experienced corporate executive with over three decades of global experience in biotechnology, pharmaceutical, and healthcare services companies. Following a successful 20-year global career with Eli Lilly culminating as CEO of Lilly Germany, Mr. Wellner led several healthcare organizations, LifeLabs/CML Healthcare, and Therapure Biopharma. He recently retired as President and Chief Executive Officer of Revera Inc., a leading global owner, operator and developer in the senior living/healthcare sector.

Mr. Wellner currently serves on the board of Andlauer Health Group where he chairs the audit committee. He also currently serves on the board of the Ontario Teachers Pension Plan; SE Health; and has previously served on the boards of FreshBooks, Novadaq Technologies, Cipher Pharmaceuticals, Diamedica, and various Revera Inc. entities, and has been an advisor to a variety of private equity, venture capital funds and family offices. He has his ICD.D Directors designation from the Rotman School of Business, and has been a guest lecturer on international business and healthcare at Harvard, Rotman and INSEAD Schools of Business. He is also a published author.

Cytophage confirms the approval of all matters presented to the shareholders at the ASM. Information on the re-elected members of the Board of Directors can be found on the Cytophage website at https://cytophage.com/our-team/.

The Company also announces that it has issued incentive stock options on July 31st, 2025 to purchase an aggregate of 170,000 common shares (the "Common Shares") of the Company at a price of $0.35 per Common Share to certain officers of the Company. The stock options vest over 24 months from the date of issue and expire July 31, 2032.

In addition on July 31st, 2025, the Company issued 1,447,500 restricted stock units (the "RSUs") to officers, directors and consultants of the Company. 1,247,500 RSUs to members of the board vest in one year, and 200,000 RSUs to the officers vest over 36 months. Each RSU entitles the holder to receive one share of the Company.

The stock options and RSUs were granted under Cytophage's Equity Incentive Plan.

 

About Cytophage 

Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. 

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature’s version of antibiotics. 

Cytophage is improving bacteria’s natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 EU countries, US, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products. 

Cytophage is using a de-risked and patented technology to advance innovative and cost competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.  

For more information on Cytophage Technologies and its innovative work in bacteriophage therapy, please visit www.cytophage.com.

For further information please contact:  

Heather Medwick, Chief Operating Officer 
heather@cytophage.com | 431 388 8873 

Cytophage Investor Alerts: https://cytophage.com/subscribe/

 

Cautionary Statement on Forward-Looking Information 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.  

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.